Drug Profile
Research programme: phospholipase A2 inhibitors - ImmuPharma
Alternative Names: IPP-201007Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ImmuPharma
- Class
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypersensitivity; Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergy in United Kingdom
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in United Kingdom
- 12 Jun 2014 Preclinical development is still ongoing in France